logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Orchid Pharma Ltd

Orchid Pharma

Small Cap•871 Employees•IPO 1993
Current Price
₹600.10
-19.65 (-3.17%)Updated
NSE :ORCHPHARMA
BSE :524372
Sector :Pharmaceuticals
Today's Range
₹595.00
₹600.10
union icon
₹617.40
52 Week Range
52W Low₹603.80
52W High₹994.15
₹600.10
union icon
Downside-0.61%
Upside65.66%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹3,365.72 Cr
Market Cap
Total market value of company
P/E Ratio
64.41
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.80
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹10.31
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
1.30%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
8.07%
ROCE
Return on Capital Employed. >15% is good
Net Margin
6.36%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
13.76%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
-29.20%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-49.20%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.14
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹249.86
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
69.80%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •Orchid Pharma maintains a strong promoter holding of 69.84%, indicating significant insider confidence and a reduced risk of hostile takeovers, which suggests a commitment to long-term success and stability.
  • •The company demonstrates a healthy operating profit margin (OPM) of 11.60%, reflecting efficiency in managing core operations and generating profits from its primary business activities effectively.

Weaknesses

5 points
  • •Orchid Pharma's latest quarterly profit shows a significant decline of -49.20%, raising concerns about earnings predictability and the company's ability to maintain consistent profitability in the near term.
  • •The stock has experienced considerable volatility, with a 52-week high of ₹1998 and a low of ₹604, indicating substantial market risk and uncertainty surrounding its future performance.

Opportunities

3 points
  • •The broader Pharmaceuticals sector, where Orchid Pharma operates, is poised for growth due to increasing global healthcare expenditure and demand for new therapeutic solutions.
  • •Expansion into emerging markets or diversification into specialized drug segments could unlock new revenue streams and reduce dependency on existing product portfolios.

Threats

4 points
  • •Intense competition from larger, more established pharmaceutical players like Sun Pharma and Cipla, with superior market caps and ROCE, could pressure Orchid Pharma's market share and margins.
  • •The highly regulated nature of the pharmaceutical industry poses a constant threat of stringent compliance requirements and potential adverse policy changes impacting operations and profitability.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹658.13+₹58.03+9.67%
R3₹635.73+₹35.63+5.94%
R2₹626.57+₹26.47+4.41%
R1₹613.33+₹13.23+2.21%
PIVOT₹604.174.070.68%
CURRENT₹600.10--
S1₹546.13-₹53.97-8.99%
S2₹568.53-₹31.57-5.26%
S3₹581.77-₹18.33-3.06%
S4₹590.93-₹9.17-1.53%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.94L
(02 Mar 2026)
+34.4% vs avg
Delivery %
68.8%
(02 Mar 2026)
+11.1% vs avg
Avg Volume (20D)
0.70L
(03 Feb - 02 Mar)
20-day average
Avg Delivery %
57.7%
(03 Feb - 02 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %

Peer Comparison

Company Name
AARTIDRUGS
Aarti Drugs Ltd
BLISSGVS
Bliss GVS Pharma Ltd
GUFICBIO
Gufic BioSciences Ltd
HIKAL
Hikal Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
RPGLIFE
RPG Life Sciences Ltd
SENORES
Senores Pharmaceuticals Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SPARC
Sun Pharma Advanced Research Company Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SUPRIYA
Supriya Lifescience Ltd
UNICHEMLAB
Unichem Laboratories Ltd
ZOTA
Zota Health Care Ltd

About

ORCHPHARMA

Orchid Pharma Ltd

Orchid Pharma Limited is an Indian pharmaceutical company specializing in the development, production, and marketing of a diverse range of pharmaceutical products. Their core offerings encompass active pharmaceutical ingredients (APIs), bulk drugs, finished dosage formulations (FDFs), and nutraceuticals. This broad portfolio allows them to cater to various sectors within the pharmaceutical industry, demonstrating a robust and diversified business model.

Within their API portfolio, Orchid Pharma focuses on key therapeutic areas. A significant portion of their business involves cephalosporins, both oral and injectable forms, used extensively in treating bacterial infections. They also manufacture veterinary products and non-antibiotic APIs, expanding their reach into different animal health and human health applications. This strategic diversification minimizes reliance on any single product or market segment.

Orchid Pharma boasts a multi-therapeutic presence across several key medical areas. These include anti-infectives (a significant area given their cephalosporin expertise), anti-inflammatory drugs, central nervous system medications, and cardiovascular drugs. The addition of nutraceuticals showcases a strategic move into the growing health and wellness market. Their product range further extends to other oral and sterile formulations, covering a wide spectrum of healthcare needs.

Beyond their manufacturing and marketing activities, Orchid Pharma offers specialized services in new drug discovery systems and pharmaceutical research and development. This positions them not only as a producer but also as a valuable partner for other pharmaceutical companies seeking innovative solutions and development expertise. Their international presence is also noteworthy, with exports to approximately 40 countries, indicating a significant global reach and market penetration.

Established in 1992 and currently a subsidiary of Dhanuka Laboratories Limited, Orchid Pharma (formerly Orchid Chemicals & Pharmaceuticals Limited) has a long history in the industry. Based in Narsinghpur, India, the company's integrated approach combining API manufacturing, formulation development, and global marketing contributes to its position as a significant player in the Indian and international pharmaceutical markets.

COMPANY FACTS - ORCHPHARMA

Registered Address

15th Floor, Tower-1, DLF Corporate Greens, Sector 74A, Narsinghpur

Gurgaon

HARYANA

IN

Tel: 914425211000

Website:https://www.orchidpharma.com/

Investor Relations:http://www.orchidpharma.com/invr_Annualreports.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 871

IPO Date: 06/09/1993

MANAGEMENT - ORCHPHARMA

Shri. Ram Agarwal

Non-Executive Non-Independent Chairman of the Board

Shri. Sunil Gupta

Chief Financial Officer

Mr. Kapil Dayya

Compliance Officer, Company Secretary

Dr. R. Sarangdhar

Vice President, Unit Head - API and FDF

Shri. Manish Dhanuka

Managing Director, Executive Director

Shri. Mridul Dhanuka

Whole Time Director

Dr. Srinivasan S

Head - CTD and IPM

Shri. Manoj Goyal

Non-Executive Independent Director

Ms. Shubha Singh

Additional Non-Executive Independent Director

Smt. Tanu Singla

Non-Executive Independent Director

Dr. Dharam Vir

Non-Executive Independent Director

Investor Questions Answered

Orchid Pharma Ltd (ORCHPHARMA) Stock FAQs

Get answers to the most common questions about Orchid Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Orchid Pharma Ltd (ORCHPHARMA) is ₹600.1. Today, the stock has declined by ₹19.65 (3.17%), trading in a range of ₹595 to ₹617.4. The stock opened at ₹614 with a trading volume of 94,288 shares.
Orchid Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,365.72 crores, P/E ratio of 64.41, ROE of 1.30%, and ROCE of 8.07%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Orchid Pharma Ltd (ORCHPHARMA) is ₹994.15, while the 52-week low is ₹603.8. Currently trading at ₹600.1, the stock is -0.9% away from its 52-week low and 39.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Orchid Pharma Ltd stock at ₹600.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 64.41 and P/B ratio of N/A. Today's performance shows a loss of 3.17%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Orchid Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹600.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Orchid Pharma Ltd's key financial metrics include: P/E Ratio: 64.41, P/B Ratio: N/A, ROE: 1.30%, ROCE: 8.07%, Dividend Yield: 0.00%, EPS: ₹10.31, Book Value: ₹249.86, Debt-to-Equity: 0.14, and Current Ratio: N/A. The company's market cap stands at ₹3,365.72 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Orchid Pharma Ltd stock opened at ₹614 and is currently trading at ₹600.1, showing a decline of ₹19.65 (3.17%). The intraday high is ₹617.4 and low is ₹595. The trading volume stands at 94,288 shares, indicating moderate market participation today.
Orchid Pharma Ltd has a Price-to-Earnings (P/E) ratio of 64.41, which means investors are willing to pay ₹64.41 for every ₹1 of earnings. With an EPS of ₹10.31, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Orchid Pharma Ltd has a market capitalization of ₹3,365.72 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹600.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Orchid Pharma Ltd has a book value of ₹249.86 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹600.1, which is 140.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Orchid Pharma Ltd has a Return on Equity (ROE) of 1.30% and Return on Capital Employed (ROCE) of 8.07%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Orchid Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Orchid Pharma Ltd has a debt-to-equity ratio of 0.14, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Orchid Pharma Ltd has an Earnings Per Share (EPS) of ₹10.31, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹600.1 and P/E ratio of 64.41, investors are paying 64.41 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Orchid Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Orchid Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Orchid Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (64.41), ROE (1.30%), debt-to-equity (0.14), and growth rates. 2) Technical Analysis - Check 52-week range (₹603.80 - ₹994.15), moving averages, and chart patterns. 3) Valuation - Compare current price (₹600.10) with book value (₹249.86) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Orchid Pharma Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹600.1 is 5901x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Orchid Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹603.80 - ₹994.15). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.14 indicates leverage. 4) Liquidity Risk - Based on trading volume of 94,288 shares. 5) Valuation Risk - P/E of 64.41 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Orchid Pharma Ltd operates in the industry with key metrics: P/E ratio of 64.41, ROE of 1.30%, market cap of ₹3,365.72 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.14), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Orchid Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹600.1, with a 52-week range of ₹603.80 to ₹994.15. Based on fundamentals like P/E (64.41), ROE (1.30%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Orchid Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹600.10. 2) Fundamental Deterioration - Declining ROE (currently 1.30%), increasing debt (D/E: 0.14), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Orchid Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.